Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung Cancer

Anlotinib is a multitargeted antiangiogenic drug, and its clinical predictor for responsive non‐small cell lung cancer (NSCLC) patients is still elusive. Here, tumor‐specific target capture is used to profile the circulating DNA of ALTER0303 (evaluating NSCLC clinical antitumor efficacy through anlo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Adv Sci (Weinh)
Autores principales: Lu, Jun, Zhong, Hua, Wu, Jun, Chu, Tianqing, Zhang, Lele, Li, Hua, Wang, Qiming, Li, Rong, Zhao, Yizhuo, Gu, Aiqin, Wang, Huimin, Shi, Chunlei, Xiong, Liwen, Zhang, Xueyan, Zhang, Wei, Lou, Yuqing, Yan, Bo, Dong, Yu, Zhang, Yanwei, Li, Baolan, Zhang, Li, Zhao, Xiaodong, Li, Kai, Han, Baohui
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6774020/
https://ncbi.nlm.nih.gov/pubmed/31592412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/advs.201900721
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares